Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
BACKGROUND
Carfilzomib is approved by the US Food and Drug Administration for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least 2 previous treatments. The approval was based on phase II trials that used a starting dose of 20 mg/m(2) escalated to a target dose of 27 mg/m(2) in cycle 2. We examined dose-outcome relationships in MM patients who received these 2 carfilzomib doses.


METHODS
Patient data from 4 cohorts of MM patients treated with single-agent carfilzomib in phase II trials were examined post hoc. The relationship between administered doses and overall response rate (ORR) was assessed using logistic regression models. Secondary analyses were performed using Cox regression models to assess the association between administered doses and time to event outcomes and using generalized estimating equations for cycle-specific response status (CSRS).


RESULTS
A total of 476 intention to treat patients were enrolled, 461 of whom were evaluable for efficacy. In the primary analysis, adjustment for cohort and baseline covariates yielded an odds ratio for ORR of 1.28 (95% confidence interval, 1.16-1.41; P < .001) for each 1 mg/m(2) increase in the average administered dose of carfilzomib per patient (up to 27 mg/m(2)). Qualitatively similar and statistically significant results were seen for the association between administered dose and CSRS, duration of response, time to progression, progression-free survival, and overall survival when adjusted for cohort and baseline covariates.


CONCLUSIONS
This post hoc analysis provides evidence for a dose-response relationship between the administered dose of carfilzomib and efficacy.
International Drug Development Institute, Louvain-la-Neuve, Belgium. Electronic address: pierre.squifflet@iddi.com.
Pierre
P
Squifflet
Service de Biostatistique et d'Epidémiologie, Institut Gustave Roussy, Université Paris-Sud, Villejuif, France.
Stefan
S
Michiels
John Theurer Cancer Center at Hackensack University, Hackensack, NJ.
David
D
Siegel
Washington University School of Medicine, St Louis, MO.
Ravi
R
Vij
Mount Sinai Medical Center, New York, NY.
Sundar
S
Jagannath
International Drug Development Institute, Louvain-la-Neuve, Belgium; Dendrix Research, Sao Paulo, Brazil.
Everardo D
ED
Saad
Onyx Pharmaceuticals, Inc, An Amgen subsidiary, South San Francisco, CA.
Kanya
K
Rajangam
Onyx Pharmaceuticals, Inc, An Amgen subsidiary, South San Francisco, CA.
Sunhee Kwon
SK
Ro
International Drug Development Institute, Louvain-la-Neuve, Belgium.
Marc
M
Buyse
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D061988:Proteasome Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D019233:Retreatment; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009842:Oligopeptides; D061988:Proteasome Inhibitors; C524865:carfilzomib
Clinical trials; Dose-response relationship; Hematologic malignancy; Overall response rate; Post hoc analysis; Proteasome inhibitor